Dr Reddy’s cracks 6% as German regulator issues six major observations

The company said that the auditor has cautioned the company that it will receive EU-GMP certification form the regulator by November 2018 only when the regulator approves the corrective and preventive action plan (CAPA) of the company. NSEBSEReddy’s LaboratoriesLoading data…

    ADD TO PORTFOLIO

    ADD TO WATCHLIST

    SHARE YOUR OULOOK

    EXPAND

    ChartsValuation & Peer ComparisonCommunity BuzzPEER COMPANIES NEW DELHI Shares of Dr Reddy’s Laboratories cracked over 6 per cent in Friday’s trade after the drugmaker informed bourses that the company has received six major observations on its formulating manufacturing facility in Visakhapatnam.

    The stock cracked 6.96 per cent to hit a low of Rs 2,069.10 on BSE. A total of 1.19 lakh shares changed hands on the counter compared with a 2-week average of 71,000 shares.

    «The regulatory authority of Germany, concluded an audit of our formulations manufacturing facility in Duvvada, Visakhapatnam, with zero critical and six major observations. Products manufactured at the facility are not currently exported to the EU,» the company said.

    The company said that the auditor has cautioned the company that it will receive EU-GMP certification form the regulator by November 2018 only when the regulator approves the corrective and preventive action plan (CAPA) of the company.

    Добавить комментарий